| 1 |
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9.
|
| 2 |
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619.
|
| 3 |
Clinical pipeline report, company report or official report of CARSGEN
|
| 4 |
ClinicalTrials.gov (NCT05205850) An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2. U.S.National Institutes of Health.
|
| 5 |
Clinical pipeline report, company report or official report of Amgen.
|
| 6 |
ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
|
| 7 |
Clinical pipeline report, company report or official report of Klus Pharma
|
| 8 |
Clinical pipeline report, company report or official report of Transcenta.
|
| 9 |
ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
|
| 10 |
Clinical pipeline report, company report or official report of Biontech
|
|
|
|
|
|
|
